Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777–2789. https://doi.org/10.1080/21645515.2016.1199310

Article  PubMed  PubMed Central  Google Scholar 

Toor SM, Syed Khaja AS, Alkurd I, Elkord E (2018) In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol 191(2):189–197. https://doi.org/10.1111/cei.13060

Article  CAS  PubMed  Google Scholar 

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7

Article  CAS  PubMed  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824

Article  PubMed  Google Scholar 

Abraham C, Kelly MP, West R, Michie S (2009) The UK National Institute for Health and Clinical Excellence public health guidance on behaviour change: a brief introduction. Psychol Health Med 14(1):1–8

PubMed  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073–4126. https://doi.org/10.1200/JCO.21.01440

Article  CAS  PubMed  Google Scholar 

Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS et al (2019) Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. J Am Coll Cardiol 74(13):1714–1727. https://doi.org/10.1016/j.jacc.2019.07.079

Article  CAS  PubMed  Google Scholar 

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749–1755. https://doi.org/10.1056/NEJMoa1609214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2(4):e000247. https://doi.org/10.1136/esmoopen-2017-000247

Article  PubMed  PubMed Central  Google Scholar 

Ma R, Wang Q, Meng D, Li K, Zhang Y (2021) Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer 21(1):38. https://doi.org/10.1186/s12885-020-07741-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN (2021) Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest 131(5):e145186. https://doi.org/10.1172/JCI145186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ (2017) Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 19(3):21. https://doi.org/10.1007/s11886-017-0835-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishikawa T, Tamiya M, Ohta-Ogo K, Ikeda Y, Hatakeyama K, Honma K, Yasui T, Shioyama W, Oka T, Inoue T, Kumagai T, Fujita M (2022) A case of lung cancer with very-late-onset immune checkpoint inhibitor-related myocarditis. CJC Open 4(7):651–655. https://doi.org/10.1016/j.cjco.2022.03.007

Article  PubMed  PubMed Central  Google Scholar 

Villatore A, Bosi C, Pomaranzi C, Cigliola A, Tateo V, Mercinelli C, Vignale D, Rizzo S, Necchi A, Peretto G (2024) Myocarditis following Pembrolizumab plus Axitinib, and Belzutifan plus Lenvatinib for renal cell carcinoma: a case report. Cardiovasc Toxicol 24(11):1168–1173. https://doi.org/10.1007/s12012-024-09906-w

Article  CAS  PubMed  Google Scholar 

Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32(7):917–925. https://doi.org/10.1016/j.annonc.2021.03.204

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. https://doi.org/10.1200/JCO.2009.26.7609

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052–1061. https://doi.org/10.1002/onco.13931

Article  PubMed  PubMed Central  Google Scholar 

Zotova L (2023) Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics 13(7):1243. https://doi.org/10.3390/diagnostics13071243

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sobol I, Chen CL, Mahmood SS, Borczuk AC (2020) Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy. Arch Pathol Lab Med 144(11):1392–1396. https://doi.org/10.5858/arpa.2019-0447-OA

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22(6):443–452. https://doi.org/10.1093/intimm/dxq026

Article  CAS  PubMed  Google Scholar 

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319–322. https://doi.org/10.1126/science.291.5502.319

Article  CAS  PubMed  Google Scholar 

Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9(12):1477–1483. https://doi.org/10.1038/nm955

Article  CAS  PubMed  Google Scholar 

Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188(10):4876–4884. https://doi.org/10.4049/jimmunol.1200389

Article  CAS  PubMed  Google Scholar 

Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ et al (2007) Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116(18):2062–2071. https://doi.org/10.1161/CIRCULATIONAHA.107.709360

Article  CAS  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK et al (2022) Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(4):387–405. https://doi.org/10.6004/jnccn.2022.0020

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO